FDA granted accelerated approval to Tazverik (tazemetostat) for the treatment of adults and pediatric patients ages 16 and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
